Gant-61 (Gli1 inhibitor), GDC-0049, and Glasdegib (Smo inhibitors) were administered one-by-one for 72 h (Figure 1A) to verify whether they exert cytotoxic activity on the following four T-ALL cell lines: Jurkat, Molt-4, DND-41, and ALL-SIL. Here, GLI1 is linked to acute lymphoblastic leukemia.